Entrapment of Hydrophobic Drugs in Nanoparticle Monolayers with Efficient Release into Cancer Cells

Kim, Chae Kyu; Ghosh, P. S.; Pagliuca, Chiara; Zhu, Zheng‐Jiang; Menichetti, Stefano; Rotello, Vincent M.

doi:10.1021/ja808137c

Cited by 308 publications

(295 citation statements)

References 23 publications

(34 reference statements)

Supporting

Mentioning

287

Contrasting

Unclassified

Order By: Relevance

“…These results seemed to confirm size dependent toxicity of AuNPs (Kim et al, 2009a;Visaria et al, 2006;Paciotti et al, 2004;El-Sayed et al, 2005b;Huang et al, 2008), an inference that has hitherto been somewhat ambivalent. On the other hand, found that the presence of sodium citrate residues on AuNPs impaired the viability in the alveolar type-II cell lines A549 and NCIH441.…”

Section: Nanotoxicitysupporting

confidence: 61%

“…The administrations of hydrophobic drugs require molecular encapsulation and it is found that nanosized particles are particularly efficient in evading the reticuloendothelial system. This approach gives a rare opportunity to prepare hybrid particles with a well-defined amount of drug and offers a new alternative for the design of nanosized drug-delivery systems (Kim et al, 2009a;Hwu et al, 2009;Gibson et al, 2007) (see Figure 4) Nanotechnology has provided for novel and powerful systems that may be used treatment of human diseases. However the majority of products, reagents and drugs being used for the development of these nanoscale systems have to be approved by the main supervising agencies, such as the FDA and EMA (Baptista, 2009).…”

Section: Drug Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Multifunctional Gold Nanocarriers for Cancer Theranostics: From Bench to Bedside and Back Again?

Conde

Tian²,

Baptista

et al. 2014

Nano-Oncologicals

View full text Add to dashboard Cite

After a quarter of century of rapid technological advances, research has revealed the complexity of cancer, a disease intimately related to the dynamic transformation of the genome. However, the full understanding of the molecular onset of this disease is still far from achieved and the search for mechanisms of treatment will follow closely.It is here that Nanotechnology enters the fray offering a wealth of tools to diagnose and treat cancer.It is indisputable that the use of gold nanocarriers has been gaining momentum as vectors for therapy and diagnostic strategies, combining the AuNPs' ease of functionalization with numerous biomolecules, high loading capacity and fast uptake by target cells. In fact, over the last decade nearly 12.000 research papers focusing on multifunctional gold nanocarriers have been published in peer-reviewed journals. Some of the described nanosystems will most likely revolutionize our understanding of biological mechanisms and push forward the clinical practice through their 2 integration in future diagnostics platforms. Nevertheless, very little gave fruitful results in order to improve a bench-to-bedside approach to translational research. On the basis of theoretical and experimental results obtained so far are we or not at the point: from bench to bedside and back again? As you will see, the answers to this question are complex, but one thing is clear: Translation into clinics is a tortuous and difficult path. Here, we provide a critical review about the available multifunctional gold nanocarriers for in vitro application and in vivo cancer targeting on nanodiagnostics and therapy.

show abstract

Section: Nanotoxicitysupporting

confidence: 61%

Section: Drug Deliverymentioning

confidence: 99%

Multifunctional Gold Nanocarriers for Cancer Theranostics: From Bench to Bedside and Back Again?

Conde

Tian²,

Baptista

et al. 2014

Nano-Oncologicals

View full text Add to dashboard Cite

show abstract

“…Significant suppression and thermal ablation of tumor growth were observed after irradiation of direct and intravenously injected PEGmodified gold nanorods to tumors in mice. [55][56][57][58] Haung et al 54) reported their experiments using gold nanorods as photothermal therapeutic agents to kill cancer cells. They conjugated gold nanorods with monoclonal antibodies recognizing proteins that are overexpressed in cancer cell lines.…”

Section: Gold Nanorods For Therapeutic Applicationsmentioning

confidence: 99%

Gold Nanorods as Nanodevices for Bioimaging, Photothermal Therapeutics, and Drug Delivery

Haine

Niidome

2017

CHEMICAL & PHARMACEUTICAL BULLETIN

View full text Add to dashboard Cite

Gold nanorods are promising metals in several biomedical applications such as bioimaging, thermal therapy, and drug delivery. Gold nanorods have strong absorption bands in near-infrared (NIR) light region and show photothermal effects. Since NIR light can penetrate deeply into tissues, their unique optical, chemical, and biological properties have attracted considerable clinical interest. Gold nanorods are expected to act not only as on-demand thermal converters for photothermal therapy but also as mediators of a controlled drug-release system responding to light irradiation. In this review, we discuss current progress using gold nanorods as bioimaging platform, phototherapeutic agents, and drug delivery vehicles.

show abstract

“…Au-NCs have attracted more attention in the past decade because of their ultra small size, excellent luminescence properties and stable structures or good storage stability [11][12][13][14]. In the recent years, gold nanoparticles have emerged for delivery of various payloads into their targets [15][16][17][18][19][20]. The payloads include small molecule drugs and big molecular proteins such as antibody and peptide.…”

Section: Introductionmentioning

confidence: 99%

The Excretion of BRCAA Antibody-Conjugated Gold Nanoclusters from Kidneys of Treated Rats

Liu¹,

Li²,

Wu³

et al. 2017

Nano BioMed ENG

View full text Add to dashboard Cite

The gold nanoclusters (Au-NCs) have emerged for delivery of various payloads such as small molecular drug and big molecular proteins due to their low immunogenicity, quick clearance and good biocompatibility. Even though they have shown great prospective in biomedical area, there are also some security problems which should be investigated further more. BRCAA1 mAb Au-NCs is a probe for gastric cancer diagnosis prepared by conjugating BRCAA1 monoclonal antibody with fluorescent Au-NCs. In this research, the renal excretion and effect on glomerulus filtration of BRCAA1 mAb AuNCs in rats were investigated. The result indicated that BRCAA1 mAb Au-NCs could be eliminated through the glomerulus filtration as early as 2 hr after the administration following the excretion of other proteins in the plasma such as immunoglobulin. Electron microscope image and pathological analysis of kidney showed that BRCAA1 mAb Au-NCs induced some structural injury such as capillaries endotheliocyte damage, pycnosis, karyorrhexis and hyalomitome acidophilia enhancement. Biochemical indexes including ALT, AST, BUN, TBIL, CK and CREA are abnormal in the period of 2 to 48 hr after the administration. The results of Western blotting and immunohistochemisty show the downregulation of three key proteins (ZO-1, Nephrin and Podocin) indicating the influence of BRCAA1 mAb Au-NCs on the foot processes of glomerular epithelial cells and shallow intercellular junctions or slit diaphragms.

show abstract

Entrapment of Hydrophobic Drugs in Nanoparticle Monolayers with Efficient Release into Cancer Cells

Cited by 308 publications

References 23 publications

Multifunctional Gold Nanocarriers for Cancer Theranostics: From Bench to Bedside and Back Again?

Multifunctional Gold Nanocarriers for Cancer Theranostics: From Bench to Bedside and Back Again?

Gold Nanorods as Nanodevices for Bioimaging, Photothermal Therapeutics, and Drug Delivery

The Excretion of BRCAA Antibody-Conjugated Gold Nanoclusters from Kidneys of Treated Rats

Contact Info

Product

Resources

About